海南双成药业股份有限公司关于公司药品生产许可证变更的公告

Core Viewpoint - The company has obtained a revised "Drug Production License" from the Hainan Provincial Drug Administration, allowing it to continue contract manufacturing for two specific drugs, which is expected to enhance production capacity and maintain stable operations without significant short-term impact on performance [1][2]. Group 1: License Details - The license change involves the continuation of contract manufacturing for the injectable drugs Aibowetai and Bivalirudin, with a contract validity of three years from the approval date [1][2]. - The production facilities are located at No. 16, Xingguo Road, Xiuying District, Haikou City, specifically in the freeze-dried powder injection workshop [1][2]. Group 2: Company Information - The company is registered at No. 16, Xingguo Road, Xiuying District, Haikou City, with a social credit code of 9146000072122491XG [1]. - The legal representative is Wang Chengdong, and the quality responsible person is Li Yuan [1]. Group 3: Production Capacity and Market Demand - The license renewal is expected to improve the company's capacity utilization and optimize production structure, thereby meeting market demand [2]. - The short-term impact on the company's performance is not expected to be significant [2].